# US 2024/0200146 A1 · Diagnostic and therapeutic methods for cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0200146 A1
- Document ID: US20240200146A1
- Status: Published application
- Kind: A1
- Application number: 18/516,552
- Filed: 2023-11-21
- Published: 2024-06-20
- Earliest claimed: 2017-09-08
- Assignees: Genentech, Inc.
- Applicants: Genentech, Inc.
- Inventors: Christiaan Nicolaas Klijn; Shiva Malek; Ivana Yen
- Web page: https://patentgrep.com/patent/US20240200146A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides diagnostic and therapeutic methods and compositions for cancer. The invention provides methods of determining whether an individual having a cancer is likely to respond to treatment comprising a pan-RAF dimer inhibitor and a MEK or PI3K inhibitor, methods of predicting responsiveness of an individual having a cancer to treatment comprising a pan-RAF dimer inhibitor and a MEK or PI3K inhibitor, methods of selecting a therapy for an individual having a cancer, and methods of treating an individual having cancer based on the presence of a biomarker of the invention (e.g., a KRAS activating mutation, e.g., a KRAS-G13D mutation, or an NRAS activating mutation).

## Claims

### Claim 1

A method of treating an individual having a cancer, the method comprising:
(a) screening a sample from the individual for an NRAS activating mutation, wherein the individual has been determined to have an NRAS activating mutation; and
(b) administering a therapeutically effective amount of a pan-RAF dimer inhibitor and a MEK inhibitor to the individual based on the presence of an NRAS activating mutation determined in step (a).

### Claim 2

A method of treating an individual having a cancer, the method comprising administering to the individual a therapeutically effective amount of a pan-RAF dimer inhibitor and a MEK inhibitor, wherein prior to treatment a sample from the individual has been screened for an NRAS activating mutation and the presence of an NRAS activating mutation in the sample has been determined.

### Claim 3 (depends on 1)

The method of claim 1, wherein screening comprises amplifying and sequencing all or a portion of the NRAS gene.

### Claim 4 (depends on 1)

The method of claim 1, wherein the MEK inhibitor is a small molecule inhibitor.

### Claim 5 (depends on 4)

The method of claim 4, wherein the small molecule inhibitor is selected from the group consisting of cobimetinib (GDC-0973), selumetinib (AZD6244), pimasertib (AS-703026), PD0325901, refametinib (BAY86-9766), binimetinib (MEK162), BI-847325, trametinib, GDC-0623, G-573, and CH5126766 (RO5126766), or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein the pan-RAF dimer inhibitor is selected from the group consisting of HM95573, LY-3009120, AZ-628, LXH-254, MLN2480, BeiGene-283, RXDX-105, BAL3833, regorafenib, and sorafenib, or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein the sample is a tissue sample, a cell sample, a whole blood sample, a plasma sample, a serum sample, or a combination thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein the cancer is selected from the group consisting of a colorectal cancer, an ovarian cancer, a lung cancer, a pancreatic cancer, a skin cancer, a kidney cancer, a bladder cancer, a breast cancer, a gastric carcinoma, an esophageal cancer, a mesothelioma, a melanoma, a head and neck cancer, a thyroid cancer, a sarcoma, a prostate cancer, a glioblastoma, a cervical cancer, a thymic carcinoma, a leukemia, a lymphoma, a myeloma, a mycosis fungoides, a Merkel cell cancer, and a hematologic malignancy.

### Claim 9 (depends on 2)

The method of claim 2, wherein the MEK inhibitor is a small molecule inhibitor.

### Claim 10 (depends on 9)

The method of claim 9, wherein the small molecule inhibitor is selected from the group consisting of cobimetinib (GDC-0973), selumetinib (AZD6244), pimasertib (AS-703026), PD0325901, refametinib (BAY86-9766), binimetinib (MEK162), BI-847325, trametinib, GDC-0623, G-573, and CH5126766 (RO5126766), or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 2)

The method of claim 2, wherein the pan-RAF dimer inhibitor is selected from the group consisting of HM95573, LY-3009120, AZ-628, LXH-254, MLN2480, BeiGene-283, RXDX-105, BAL3833, regorafenib, and sorafenib, or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 2)

The method of claim 2, wherein the sample is a tissue sample, a cell sample, a whole blood sample, a plasma sample, a serum sample, or a combination thereof.

### Claim 13 (depends on 2)

The method of claim 2, wherein the cancer is selected from the group consisting of a colorectal cancer, an ovarian cancer, a lung cancer, a pancreatic cancer, a skin cancer, a kidney cancer, a bladder cancer, a breast cancer, a gastric carcinoma, an esophageal cancer, a mesothelioma, a melanoma, a head and neck cancer, a thyroid cancer, a sarcoma, a prostate cancer, a glioblastoma, a cervical cancer, a thymic carcinoma, a leukemia, a lymphoma, a myeloma, a mycosis fungoides, a Merkel cell cancer, and a hematologic malignancy.
